Cargando…

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus

BACKGROUND AND OBJECTIVES: Linagliptin is a dipeptidyl peptidase (DPP)-4 inhibitor, used to treat type 2 diabetes mellitus (T2DM). Population pharmacokinetic and pharmacodynamic analyses were performed to characterize the impact of clinically relevant intrinsic/extrinsic factors (covariates) on lina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Retlich, Silke, Duval, Vincent, Graefe-Mody, Ulrike, Friedrich, Christian, Patel, Sanjay, Jaehde, Ulrich, Staab, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486092/ https://www.ncbi.nlm.nih.gov/pubmed/25637172 http://dx.doi.org/10.1007/s40262-014-0232-4

Ejemplares similares

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes
por: Sarashina, Akiko, et al.
Publicado: (2016)

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
por: Gross, Jorge Luiz, et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
por: Baron, Kyle T., et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
por: Morello, Candis M
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
por: Alghamdi, Wael A., et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus
por: Sun, Lin, et al.
Publicado: (2011)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients
por: Arshad, Usman, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
por: Kim, Choon Ok, et al.
Publicado: (2020)

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design
por: Reddy, Micaela B., et al.
Publicado: (2015)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
por: Miyawaki, Yoshia, et al.
Publicado: (2018)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
por: Chen, Bing, et al.
Publicado: (2022)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_doetcp323qpcb0ucm7ogp28j3b